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Indianapolis, IndianaABSTRACT Monoclonal antibodies are typically monomeric and nonviscous at low concentrations, yet they display highly
variable associative and viscous behavior at elevated concentrations. Although measurements of antibody self-association
are critical for understanding this complex behavior, traditional biophysical methods are not capable of characterizing such
concentration-dependent self-association in a high-throughput manner. Here we describe a nanoparticle-based method,
termed self-interaction nanoparticle spectroscopy, that is capable of rapidly measuring concentration-dependent self-interac-
tions for three human monoclonal antibodies with unique solution behaviors. We demonstrate that gold nanoparticles conju-
gated with antibodies at low protein concentrations (<40 mg/mL) display self-association behavior (as measured by the
interparticle distance-dependent plasmon wavelength) that is well correlated with static light-scattering measurements ob-
tained at three orders of magnitude higher antibody concentrations. Using this methodology, we find that the antibodies
display a complex pH-dependent self-association behavior that is strongly influenced by the solution ionic strength. Impor-
tantly, we find that a polyclonal human antibody is nonassociative for all solution conditions evaluated in this work, suggesting
that antibody self-association is more specific than previously realized. We expect that our findings will guide rational manip-
ulation of antibody phase behavior, and enable studies that elucidate sequence and structural determinants of antibody self-
association.INTRODUCTIONOne of the most fundamental properties of proteins is their
propensity to self-associate. In some cases, protein self-
association is linked to normal biological function (e.g.,
assembly of microtubules and actin filaments) (1,2). In other
cases, proteins inappropriately self-associate and aggregate,
leading to several human disorders (e.g., Alzheimer’s and
prion diseases) (3,4) and the inactivation of therapeutic pro-
teins (e.g., antibodies) (5–9). Given the deleterious nature of
protein aggregation, it is critical to elucidate the underlying
protein self-interactions so that we can develop systematic
strategies to prevent this undesirable behavior.
Monoclonal antibodies (mAbs) are an important class
of therapeutic proteins that display highly complex and
poorly understood self-association behavior (10–13). These
large, multidomain proteins possess two identical antigen-
binding domains (Fabs) that can participate in homotypic
interactions with themselves and heterotypic interactions
with their constant (Fc) domains (11). Given the high se-
quence similarity between mAb variants, it would be logical
to assume that mAbs display similar self-association and
solubility behavior. However, the highly variable comple-
mentarity determining regions (CDRs) on the surface of
Fabs contribute disproportionately to mAb self-association
(11,14,15), as single point mutations within CDRs canSubmitted May 12, 2011, and accepted for publication August 22, 2011.
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antibody fragments (14–16).
The self-association behavior of mAbs is highly concen-
tration-dependent (5,17). Generally, mAbs are well behaved
at low protein concentrations (<10 mg/mL) and display
a modest propensity to self-associate. However, at the
high concentrations required for therapeutic applications
(>50 mg/mL), mAbs display highly variable self-associa-
tion behavior that is difficult to predict based on antibody
sequence or structure ((18,19) for recent progress). Such
associative behavior can lead to viscous, opalescent, and/
or aggregated antibody solutions (6,20). Antibodies (and
other proteins) self-associate at high concentrations via
interactions sampled both frequently (e.g., Coulombic inter-
actions) and infrequently (e.g, induced dipole interactions)
at low concentrations (17,21).
Therefore, it is critical to measure the self-association
behavior of mAbs at high concentrations to understand their
complex phase behavior (22–25). This ambitious goal is
difficult to achieve in practice because many analytical
methods that are capable of measuring protein self-interac-
tions in dilute solutions (26–28) are not amenable to
measuring such interactions in highly concentrated solu-
tions, especially in a high-throughput manner (14,29,30).
A second limitation is that a large amount of antibody is
required to analyze high-concentration self-association
behavior, which restricts analysis of these complex
interactions.doi: 10.1016/j.bpj.2011.08.036
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nanoparticle-based assay, termed self-interaction nano-
particle spectroscopy (SINS), to measure protein self-
interactions (31,32). We reason that 1) antibodies at low
concentrations (<40 mg/mL) can be adsorbed on gold nano-
particles to generate antibody clusters in which the local
protein concentration is extremely high (>100 mg/mL);
and 2) the interparticle distances between the polyvalent
antibody-gold conjugates can be determined by multibody
interactions that occur in concentrated antibody solutions.
This approach builds on our previous high-throughput
analysis of globular protein self-association (31,32), but
is distinct in that it seeks to evaluate high-concentration
self-association behavior for large, multidomain proteins.
Our choice of gold nanoparticles is based on several
factors, including the excellent stability and functionality
of antibodies adsorbed on gold particles (33,34), as evi-
denced by decades of use of these conjugates in immuno-
histochemistry studies (35,36). We also chose to use gold
particles because of their interparticle distance-dependent
optical properties (37–39). The plasmon wavelength (lp),
i.e., the wavelength corresponding to maximal absorbance
of gold colloid, shifts to greater values as the separation
distance between nanoparticles is reduced. We seek to
exploit the sensitivity of the plasmon wavelength to changes
in the interparticle distances between antibody-gold con-
jugates to quantify the extent of antibody self-association.
Herein, we demonstrate that SINS is well suited to
characterize the concentration-dependent self-association
behavior of multiple mAbs, and we employ this method-
ology to elucidate complex antibody self-association
behavior that is strongly dependent on solution pH and ionic
strength.MATERIALS AND METHODS
Materials
Three human Ig4 mAbs (expressed in CHO cells) were provided by Eli
Lilly and Company (Indianapolis, IN). Gold nanoparticles (20 nm) were
obtained from Ted Pella (15705-1; Redding, CA). Traut’s reagent (PI-
26101), Ellman’s reagent (PI-22582), potassium chloride (BP366-500),
potassium hydroxide (ACS grade, P250), glacial acetic acid (99.5% pure;
124040010), recombinant Protein A (PI-21184), and a MicroBCA assay
kit (PI-23235) were obtained from Thermo Fisher Scientific (Waltham,
MA). Citric acid (ACS grade, 251275), sodium citrate (USP grade,
S1804), dibasic sodium phosphate dihydrate (ACS grade, 71643), mono-
basic potassium phosphate (ACS grade, P0662), potassium acetate
(P1190), hydrochloric acid (37% ACS grade, 320331), bovine serum
albumin (A2153), polyclonal IgG from human serum (I4506), and mercap-
topolyethylene glycol monomethyl ether (5000 MW, 11124) were pur-
chased from Sigma-Aldrich (St. Louis, MO). Sodium chloride (102892)
was obtained from MP Biomedicals (Solon, OH). All experiments were
carried out at room temperature (23 5 2C). Antibody concentrations
were determined via absorption measurements (280 nm) using extinction
coefficients of 1.46 (mAb1), 1.47 (mAb2), and 1.61 (mAb3) mL/(mg$cm).
The extinction coefficients were calculated using an adaptation of the
Edelhoch method (40), and verified experimentally using amino acid
analysis.Biophysical Journal 101(7) 1749–1757METHODS
Antibody immobilization
Each antibody (30 mM) that was thiolated before immobilization was modi-
fied with Traut’s reagent (180 mM) for 1 h (pH 8.0, PBS, 2 mM EDTA,
23C). The modified antibodies were then buffer exchanged (Zeba desalting
columns; Thermo Fisher Scientific) into acetate buffer (20 mM potassium
acetate, pH 4.3). The extent of thiolation was quantified by means of
Ellman’s assay. One part of wild-type or thiolated antibody solution
(400 mg/mL) was mixed with nine parts of gold particles (4.7 
1012 particles/mL) and incubated overnight at 23C. The next day, the
conjugates were pelleted (15,000 rpm for 10 min), the supernatant (90%
of starting volume) was discarded, and the conjugates were resuspended
in immobilization buffer (2 mM potassium acetate, pH 4.3) supplemented
with thiolated PEG (5000 MW; 0.1 mM). After 1 h, the conjugates were
pelleted and resuspended in immobilization buffer.Dynamic light scattering
Dynamic light scattering (DLS) analysis was conducted using a DynaPro
Titan light-scattering setup (Wyatt, Santa Barbara, CA). Gold particles
and antibodies were filtered separately with a 0.22 mm PVDF filter and
then combined as described above. The conjugates were transferred into
disposable Eppendorf light-scattering cuvettes without further processing.
Antibody samples (0.5 mg/mL) in immobilization buffer were filtered
directly into the light-scattering cuvette. For solutions containing nanopar-
ticles, the laser power was adjusted accordingly to maintain a count rate of
1–2 million counts per second. For antibody solutions without nanopar-
ticles, the laser power was adjusted to obtain hundreds of thousands of
counts per second. The scattering data were fit (Dynamics software; Wyatt)
assuming the scatterers to be Rayleigh spheres.Plasmon wavelength measurements
The purified antibody-gold conjugates were added to various buffered stock
solutions in a volumetric ratio of 4:1, respectively, in clear 96-well micro-
titer plates. The resulting pH of these solutions was adjusted to 4.3 or 6/6.5,
and the final buffer concentrations were 20 mM acetate (pH 4.3) and 10 mM
citrate (pH 6/6.5). The absorption spectra (400–700 nm) of each sample
(175 mL) were measured with a Tecan Safire2 plate reader. We identified
the plasmon wavelength by fitting the absorption spectra to a quadratic
polynomial (40 data points, intervals of 1 nm) and evaluating the wave-
length at which the first derivative of the quadratic function was zero.Antibody adsorption analysis
Antibodies at varying concentrations (5–40 mg/mL) were adsorbed on gold
particles overnight (9:1 volumetric ratio of gold/antibody, 1 mL total
volume). The next day, the conjugates were pelleted and resuspended twice
(90% of supernatant removed and replaced each time). The conjugates were
then resuspended in microBCA assay solution (Thermo Fisher Scientific),
developed for 2 h at 32C, the absorbance was measured at 562 nm, and
the adsorbed concentration was calculated using a standard curve developed
with the same antibodies.Static light scattering
Weight average molecular weight (WAMW) values were determined for
each antibody (6 and 42 mg/mL) in different buffer systems using static
light scattering (SLS). Measurements were performed at room temperature
(235 2C) with the use of an LSE-5003 multiple tau digital correlator and
CGS-3 compact goniometer system (ALV, Langen, Germany). Samples
were dialyzed against excess buffer, and final antibody concentrations
Antibody Self-Association Analysis 1751were determined with an Agilant 8453 UV-visible spectrophotometer
(Agilent Technologies, Santa Clara, CA). Samples were filtered through
0.22-mm, 13-mm Millex GV durapore membrane filters (Millipore, Bil-
lerica, MA) immediately before measurement. The intensities at multiple
angles (70–110) were averaged because scattering was independent of
the scattering angle. The WAMW values were calculated as follows:
WAMW ¼

Kc
Rex
1
; (1)
where K is an optical constant, c is the protein mass concentration, and Rex
is the excess Rayleigh ratio (41). The value of the refractive index
increment (dn/dc) used to calculate K was 0.185 mL/g.Protein A binding analysis
Protein A from Staphylococcus aureus (45 kDa; Pierce) prepared at 80 and
160 mg/mL (PBS, pH 7) was mixed with antibody-gold conjugates (20-fold
concentrated, free antibody removed) in immobilization buffer in a 1:1
volumetric ratio, and incubated for 90 min. Afterward, the samples were
centrifuged for 10 min (15,000 rpm), and the concentration of Protein A
remaining in the supernatant was assayed using the microBCA assay
(Pierce). The amount of bound Protein A was calculated as the difference
between the initial and final amounts of Protein A in solution, and BSA-
gold conjugates were used to account for nonspecifically bound Protein
A. Separately, equal volumes of Protein A (80 and 160 mg/mL in PBS
at pH 7) and unconjugated mAbs (in immobilization buffer) were mixed
for 90 min. Afterward, the Protein A-mAb solutions were spin-filtered
(50 kDa molecular mass cutoff filters; Millipore) for 20 min
(12,000 rpm) to separate bound and unbound Protein A. We determined
the filtrate concentration of unbound Protein A using the microBCA assay,
and calculated the amount of bound Protein A via mass balance. Protein A
solutions without antibody were also filtered to account for nonspecific
protein retention.FIGURE 1 Immobilization of mAbs on gold nanoparticles. (A) UV-
visible absorbance spectra of gold particles (black circles), gold-mAb1
conjugates (gray circles), and gold-mAb2 conjugates (white triangles).
(B) DLS analysis of gold particles, antibodies (wild-type and thiolated),
and gold-antibody conjugates.RESULTS
Assembly and characterization of gold-antibody
conjugates
Toward our goal of using antibody-gold conjugates to char-
acterize antibody self-association, we first sought to immo-
bilize two mAbs (mAb1 and mAb2) on gold nanoparticles
(20 nm) in a manner that would result in a near-monolayer
coverage. We tested two approaches for immobilizing anti-
bodies: one in which the wild-type antibody is directly
adsorbed, and the other in which primary amines on the anti-
body surface are converted to thiol moieties to facilitate
immobilization. We used Traut’s reagent to convert approx-
imately one primary amine per antibody to a thiol moiety,
and confirmed this modification using Ellman’s reagent.
Next, we investigated a range of pH and ionic strength
values to identify conditions that would lead to antibody
immobilization for both wild-type and thiolated antibodies
while promoting high colloidal stability of the conjugates.
To that end, we first measured the visible spectra of mAb1
and mAb2 conjugates to evaluate solution conditions that
would promote plasmon shifts of ~1% relative to nonconju-
gated gold particles, characteristic of changes in the dielec-
tric environment surrounding nanoparticles due to proteinadsorption (42,43). We found that moderately acidic pH
(4.3) in the absence of salt led to such plasmon shifts
(6–7 nm) for both wild-type and thiolated antibodies
(Fig. 1 A and Fig. S1 in the Supporting Material), consistent
with antibody adsorption without association between
conjugates. In contrast, we were unable to identify such
solution conditions at higher (pH 6–7) and/or ionic strength
(50–300 mM; data not shown). We also found that wild-type
and thiolated antibodies display indistinguishable plasmon
shifts upon antibody adsorption at pH 4.3 (Fig. 1 A and
Fig. S1).
We also used DLS to characterize the size of mAb1 and
mAb2 conjugates (Fig. 1 B). The measured radius of the
gold colloid (9.3 5 1.1 nm) is close to its nominal value
(10 nm). Moreover, the radii of both wild-type and thiolated
antibodies (4.7–5.4 nm) are close to each other and consis-
tent with previous reports (44,45). The radii of the gold-anti-
body conjugates (19–23 nm) for wild-type and thiolated
antibodies are similar and consistent with a monolayer
coverage of antibody (19–21 nm). Nevertheless, we also
quantified the amount of immobilized protein for bothBiophysical Journal 101(7) 1749–1757
1752 Sule et al.wild-type and thiolated antibodies (Fig. S2), and found im-
mobilization densities (3.0–4.1 mg/m2 or 13–17 antibodies/
particle) that are similar to literature values (1–5 mg/m2)
(42,43,46,47) and theoretical values for a monolayer surface
coverage (2–5 mg/m2) (46) that vary based on the orienta-
tion of the adsorbed antibody. We conclude that thiolation
is unnecessary for antibody immobilization, and thus we
further investigate only wild-type antibodies conjugated to
gold colloid.
We also evaluated whether the immobilized antibodies
are randomly oriented on the gold surface. To accomplish
this, we investigated binding of Protein A to the conjugated
mAbs. We hypothesized that randomly oriented antibodies
would retain half of their Protein A binding activity because
half of the binding sites would be blocked by the gold
surface. We found that both mAb1- and mAb2-gold conju-
gates retain approximately half of their Protein A binding
activity (52% for mAb1 and 53% for mAb2) relative to
unconjugated mAbs (Fig. S3). Our findings suggest that
mAb1 and mAb2 are immobilized in a near-random distri-
bution of antibody orientations.FIGURE 2 Analysis of variable antibody self-association at near-neutral
pH. (A) Plasmon wavelengths (lp) of mAb1 and mAb2 conjugates at pH 6.5
and 6, respectively. (B) SLS measurements of WAMWvalues for mAb1 and
mAb2 at 6 mg/mL.Comparison of SINS and light-scattering
measurements
We next investigated the self-association behavior of both
mAb1 and mAb2 conjugates at near-neutral pH (6–6.5).
We find that the plasmon wavelengths for mAb2 conjugates
assembled at pH 4.3 (lp ¼ 530.75 0.1 nm) increase signif-
icantly when the solution pH is increased to pH 6 (Fig. 2A; lp
> 535 nm). Moreover, the plasmon wavelength for mAb2
conjugates at pH 6 is lower at 150 mM NaCl than at
50 mM NaCl. In contrast, the plasmon wavelengths for
mAb1 conjugates at pH 6.5 (Fig. 2 A; lp ¼ 530.8 5
0.1 nm) are indistinguishable from those at low pH (lp ¼
530.75 0.1 nm). We performed SLS measurements of the
WAMW (6mg/mL) for each antibody and solution condition
to evaluate whether the SINS measurements are reflective
of antibody self-association in the absence of nanoparticles
(Fig. 2 B). We expected that attractive antibody self-
interactions (as indicated by increased values of WAMW)
would correspond to decreased separation distances between
antibody-gold conjugates (as indicated by increased plas-
mon wavelengths). We found that large WAMW values
correspond to large plasmon wavelengths (Fig. 2).
Nevertheless, we sought to more rigorously evaluate the
relationship between the SINS and light-scattering measure-
ments over a wider range of ionic strengths (Fig. 3). Relative
to noninteracting gold-antibody conjugates, we find that
mAb1 is nonassociative at pH 6.5 (0–300 mM NaCl) but
does associate at pH 4.3 at sodium chloride concentrations
R25 mM (Fig. 3 A). In contrast, mAb2 is highly associative
at near-neutral pH (pH 6; 0–300 mM NaCl) and weakly
associative at pH 4.3 (Fig. 3 B). We confirmed that the
amount of immobilized antibody was similar for conjugatesBiophysical Journal 101(7) 1749–1757in different solution conditions (Fig. S4), and that the buffer
type weakly affected the SINS measurements (Fig. S5). Of
importance, the light-scattering measurements (6 mg/mL)
are consistent with our plasmon wavelength measurements,
because mAb1 is more associative at pH 4.3 than at pH 6.5
(Fig. 4 A), and the inverse is true for mAb2 (Fig. 4 B).
To provide a more quantitative comparison between our
SINS and light-scattering results, we plotted the plasmon
wavelengths for mAb1 and mAb2 (32 mg/mL) against
WAMW values (normalized to the approximate monomer
molecular mass of 150 kDa) measured at low (6 mg/mL)
and high (42 mg/mL) antibody concentrations (Fig. 5). In
both cases, we find that plasmon wavelengths are well cor-
related with normalized WAMW values (R2 ¼ 0.89–0.97).
We also observe a better correlation between plasmon wave-
lengths and WAMW values measured at higher antibody
concentrations (R2 ¼ 0.97) compared with those obtained
at lower concentrations (R2 ¼ 0.89).
To evaluate the robustness of SINS to measure self-
association of other mAbs, we characterized a third anti-
body (mAb3). We performed SLS analysis of mAb3 at
FIGURE 4 SLS analysis of antibody self-association as a function of pH
and ionic strength. WAMW measurements for (A) mAb1 and (B) mAb2
(6 mg/mL) at pH 4.3 (solid circles) and pH 6.5 (open triangles).
FIGURE 3 SINS analysis of antibody self-association as a function of pH
and ionic strength. Plasmon wavelengths (lp) of (A) gold-mAb1 and (B)
gold-mAb2 conjugates at pH 4.3 (solid circles) and pH 6.5/6 (open
triangles).
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less associative than mAb2 (Fig. 6 A and Fig. S6). To eval-
uate mAb3 self-association using SINS, we first character-
ized the size and immobilization density of mAb3-gold
conjugates. We found that the mAb3 conjugates are similar
in size (18.5 5 1.5 nm; Fig. S6) and antibody loading
(2.5 5 0.1 mg/m2) to the mAb1 and mAb2 conjugates
(Fig. 1 B and Fig. S2). The plasmon wavelengths for
mAb3 conjugates are intermediate to those for mAb1 and
mAb2, in agreement with the light-scattering results
(Fig. 6 B and Fig. S6).Specificity of SINS measurements
To evaluate the specificity of mAb self-interaction measure-
ments, we sought to determine whether a polyclonal IgG
would show unique self-association behavior relative to
the mAbs. We hypothesized that the molecular diversity of
a polyclonal mixture of antibodies would render it less asso-
ciative than the mAbs. To test this hypothesis, we firstprepared polyclonal antibody-gold conjugates in the same
manner employed for each mAb. We found that the immo-
bilization density (3.85 0.6 mg/m2) and size of the conju-
gates (18.65 0.6 nm; Fig. S7) were consistent with those of
their monoclonal counterparts (Fig. 1 B, Fig. S2, and
Fig. S6). Next, we evaluated the self-association behavior
of the polyclonal antibody conjugates at the same pH and
ionic strength values analyzed for each mAb (Fig. 7). We
found that the polyclonal antibody was nonassociative at
all solution conditions examined, revealing that mAbs are
significantly more associative than the nonspecific antibody
mixture.DISCUSSION
A major outcome of this work is our demonstration that
SINS measurements of antibody self-interactions at low
concentrations (<40 mg/mL) are well correlated with those
obtained by light scattering at three orders of magni-
tude higher antibody concentrations. We demonstrate that
polyvalent antibody-gold conjugates can be used to evaluateBiophysical Journal 101(7) 1749–1757
FIGURE 7 Self-association behavior of a polyclonal antibody as a func-
tion of pH and ionic strength. Plasmon wavelengths (lp) of polyclonal anti-
body-gold conjugates at pH 4.3 (black circles), pH 6 (gray squares) and
pH 6.5 (white triangles).
FIGURE 5 Correlation between SINS and SLS measurements of anti-
body self-association. Plasmon wavelengths (lp) for gold-antibody conju-
gates plotted versus WAMW values obtained at antibody concentrations
of (A) 6 and (B) 42 mg/mL.
FIGURE 6 Comparison of self-association behavior for three mAbs.
Measurements of (A) WAMW (6 mg/mL) and (B) plasmon wavelengths
(lp) at pH 6.5 (mAb1 and mAb3) and pH 6 (mAb2). The salt concentration
was 150 mM NaCl.
1754 Sule et al.multibody interactions that occur at elevated antibody
concentrations. Importantly, our SINS measurements are
better correlated with high-concentration (42 mg/mL)
light-scattering measurements than with low-concentration
(6 mg/mL) measurements. This finding is consistent with
our hypothesis that SINS can enable analysis of high-
concentration antibody self-association due to the polyvalent
display of antibodies on gold particles.
The simplicity of using SINS to measure concentration-
dependent antibody self-association in a parallel, high-
throughput manner is another important outcome of our
work. We conducted our measurements in 96-well micro-
titer plates with a standard absorbance plate reader. Cur-
rently, we require ~15 min and 400 mg of antibody to
measure plasmon wavelengths for 100 samples. We conser-
vatively estimate that the time and amount of antibody could
be reduced to 5 min and 100 mg per 100 samples by reducing
the antibody concentration, the number of points collected
for each visible absorption spectrum, and the sample volume
using 384-well plates.Biophysical Journal 101(7) 1749–1757We investigated multiple methods of immobilizing anti-
bodies on nanoparticles to evaluate whether chemical modi-
fication of antibodies is necessary for preparing stable
antibody-gold conjugates for SINS analysis. We found
Antibody Self-Association Analysis 1755that all antibodies studied in this work adsorbed well on gold
regardless of whether they were thiolated. All of the unmod-
ified antibodies lacked free thiol groups, confirming that
residues other than cysteine mediate adsorption (48–51).
Our finding that wild-type antibodies are well adsorbed on
gold particles is consistent with much previous work
demonstrating that stable antibody-gold conjugates can be
generated by simple noncovalent adsorption (35,52,53).
We also made two particularly important methodological
advances in performing SINS in this work that deserve
further consideration. First, we identified solution condi-
tions (pH 4.3, 2 mM acetate) for antibody immobilization
in which antibody-gold conjugates do not associate. This
mildly acidic pH and low ionic strength condition enabled
us to pellet the antibody-gold conjugates multiple times to
remove free protein without causing the conjugates to
aggregate. Second, we adsorbed thiolated PEG on the anti-
body-gold conjugates to reduce nonspecific interactions.
Although thiolated PEG does not displace bound antibody
(Fig. S2), it significantly improves the correlation between
SINS and light-scattering measurements (Fig. 4 B and
Fig. S8).
The efficiency of SINS enabled us to identify complex
pH-dependent patterns of self-association for mAb1 and
mAb2. Both antibodies are associative at low pH (4.3) and
salt concentrations >25 mM NaCl, consistent with previous
reports for other mAbs (54,55). At near-neutral pH (6–6.5),
mAb2 is much more associative than mAb1. This solu-
tion behavior appears to involve electrostatic interactions,
because the association is attenuated with salt (14,56).
The striking difference between solution conditions that
minimize self-association for mAb1 and mAb2 highlights
the complexity of antibody self-association, and the need
to measure these interactions to manipulate antibody solu-
tion properties in a rational manner.
In contrast to the mAbs, the lack of self-association for
the polyclonal antibody over a wide range of solution condi-
tions is striking and suggests that mAb self-association is
more specific than is generally expected. Our findings are
supported by previous work demonstrating that viscosity
measurements of concentrated polyclonal antibody solu-
tions are well described by hard sphere models (which
consider only excluded volume contributions to intermolec-
ular interactions) (57), unlike several mAbs that are poorly
described by such models (11,23). A potential explanation
for this behavior is that the polyclonal nature of this anti-
body mixture prevents attractive intermolecular interac-
tions (57). Neal and co-workers (58) demonstrated that
a small number of pairwise configurations with a high level
of geometric complementarity (e.g., the crystal contacts)
dominate the overall strength of globular protein self-
association. Based on the importance of self-complemen-
tarity in protein self-association, we posit that polyclonal
antibodies are incapable of forming such complementary
pairwise configurations and therefore fail to associate.This hypothesis awaits computational and further experi-
mental verification.CONCLUSIONS
In summary, we have demonstrated a high-throughput
method for measuring the concentration-dependent self-
association of mAbs at low protein concentrations. We
believe that clustering antibodies and other proteins around
nanometer-sized particles is an important approach for
understanding high-concentration solution behavior. It is
likely that variations in nanoparticle size and composition,
as well as in protein immobilization density and chemistry,
will lead to additional advances in SINS characterization of
antibody self-interactions at low and high protein concentra-
tions. We expect that implementing SINS and related
methods to characterize the self-association behavior of
homologous libraries of antibodies will reveal key sequence
and structural determinants of concentration-dependent
antibody self-association.SUPPORTING MATERIAL
Eight figures are available at http://www.biophysj.org/biophysj/supplemental/
S0006-3495(11)01009-5.
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